Clinical Research Directory
Browse clinical research sites, groups, and studies.
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
Sponsor: UNC Lineberger Comprehensive Cancer Center
Summary
The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is not known if this information is helpful in determining treatment when breast cancer has become metastatic. HARMONY will give the treating physician of each participant the molecular subtype of the tumor based on PAM50 testing. The usefulness of this information will be determined through the physician survey. Finding out the molecular subtype of each tumor also allows the investigators to determine if the molecular subtype is different from what is expected based on the clinical subtype. This study will help determine how new types of information about tumors can help choose treatments for MBC
Official title: HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2018-11-06
Completion Date
2030-12-15
Last Updated
2026-01-30
Healthy Volunteers
No
Conditions
Interventions
Intrinsic Subtyping of Primary Breast Cancer
Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
Locations (2)
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
UNC Rex Healthcare
Raleigh, North Carolina, United States